Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution

[1]  Neil A. Miller,et al.  The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database , 2017, Clinical pharmacology and therapeutics.

[2]  R. Kuroki,et al.  Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. , 2017, Biochemistry.

[3]  P. Hlavica.  Challenges in assignment of allosteric effects in cytochrome P450-catalyzed substrate oxidations to structural dynamics in the hemoprotein architecture. , 2017, Journal of inorganic biochemistry.

[4]  J. Halpert,et al.  Conformational Mobility in Cytochrome P450 3A4 Explored by Pressure-Perturbation EPR Spectroscopy. , 2016, Biophysical journal.

[5]  J. Halpert,et al.  Interactions among Cytochromes P450 in Microsomal Membranes , 2014, The Journal of Biological Chemistry.

[6]  T. Blundell,et al.  Combining in silico protein stability calculations with structure-function relationships to explore the effect of polymorphic variation on cytochrome P450 drug metabolism. , 2013, Current drug metabolism.

[7]  J. Halpert,et al.  Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of α-naphthoflavone. , 2013, The Biochemical journal.

[8]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[9]  T. Poulos,et al.  Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. , 2013, Dalton transactions.

[10]  A. Archakov,et al.  Prediction of amino acid residues participated in substrate recognition by cytochrome P450 subfamilies with broad substrate specificity , 2013, Journal of molecular recognition : JMR.

[11]  L. Cavallari,et al.  Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism , 2012, Clinical pharmacology and therapeutics.

[12]  W. Backes,et al.  Formation of P450 · P450 complexes and their effect on P450 function. , 2012, Pharmacology & therapeutics.

[13]  Karel Berka,et al.  Is there a relationship between the substrate preferences and structural flexibility of cytochromes P450? , 2012, Current drug metabolism.

[14]  J. Blackburn,et al.  An expanded, unified substrate recognition site map for mammalian cytochrome P450s: analysis of molecular interactions between 15 mammalian CYP450 isoforms and 868 substrates. , 2011, Current drug metabolism.

[15]  Dongxu Sun,et al.  Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  Alexander Zawaira,et al.  On the deduction and analysis of singlet and two-state gating-models from the static structures of mammalian CYP450. , 2011, Journal of structural biology.

[17]  D. Nelson,et al.  Cytochrome P450 (CYP) Gene Superfamily , 2011 .

[18]  Eric F. Johnson,et al.  CYP2C8 Exists as a Dimer in Natural Membranes , 2010, Drug Metabolism and Disposition.

[19]  Ruth Nussinov,et al.  How Does the Reductase Help To Regulate the Catalytic Cycle of Cytochrome P450 3A4 Using the Conserved Water Channel? , 2010, The journal of physical chemistry. B.

[20]  Patrick Marais,et al.  Exhaustive computational search of ionic-charge clusters that mediate interactions between mammalian cytochrome P450 (CYP) and P450-oxidoreductase (POR) proteins , 2010, Comput. Biol. Chem..

[21]  F. Guengerich,et al.  Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase , 2009, Nature Protocols.

[22]  T. Miyata,et al.  Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects , 2009, Drug Metabolism and Disposition.

[23]  Koujirou Yamamoto,et al.  Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone , 2008, Drug Metabolism and Disposition.

[24]  Y. Kokubo,et al.  Genetic Variations of CYP2C9 in 724 Japanese Individuals and Their Impact on the Antihypertensive Effects of Losartan , 2008, Hypertension Research.

[25]  Michal Otyepka,et al.  Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. , 2008, The journal of physical chemistry. B.

[26]  S. Sligar,et al.  Allosteric mechanisms in cytochrome P450 3A4 studied by high-pressure spectroscopy: pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket. , 2007, Biochemistry.

[27]  J. Halpert,et al.  Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W. , 2007, Archives of biochemistry and biophysics.

[28]  F Peter Guengerich,et al.  Multiple Sequential Steps Involved in the Binding of Inhibitors to Cytochrome P450 3A4* , 2007, Journal of Biological Chemistry.

[29]  N. Kamatani,et al.  Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese , 2006, Pharmacogenetics and genomics.

[30]  J. Gala,et al.  CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population , 2005, Pharmacogenetics and genomics.

[31]  S. Sligar,et al.  Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. , 2005, Biochemistry.

[32]  H. Zhou,et al.  Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13 , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  H. McLeod,et al.  CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY , 2005, Drug Metabolism and Disposition.

[34]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[35]  W. Atkins,et al.  Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. , 2005, Annual review of pharmacology and toxicology.

[36]  A. Daly,et al.  Pharmacogenetics of the cytochromes P450. , 2004, Current topics in medicinal chemistry.

[37]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[38]  H. Mohrenweiser,et al.  Discovery of new potentially defective alleles of human CYP2C9. , 2004, Pharmacogenetics.

[39]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[40]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[41]  F Peter Guengerich,et al.  Functional characterization of four allelic variants of human cytochrome P450 1A2. , 2004, Archives of biochemistry and biophysics.

[42]  Jean-Paul Renaud,et al.  Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. , 2003, Biochemical and biophysical research communications.

[43]  James R. Halpert,et al.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[45]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[46]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[47]  H. Klenk,et al.  Identification and functional characterization of eight CYP3A4 protein variants. , 2001, Pharmacogenetics.

[48]  M. Ingelman-Sundberg,et al.  Role of CYP2C9 polymorphism in losartan oxidation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[49]  A. Y. Lu,et al.  Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.

[50]  T. Kamataki,et al.  A novel single nucleotide polymorphism altering stability and activity of CYP2a6. , 2001, Biochemical and biophysical research communications.

[51]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[52]  S. Higuchi,et al.  Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. , 2000, Therapeutic drug monitoring.

[53]  J. Peterson,et al.  Association of cytochromes P450 with their reductases: opposite sign of the electrostatic interactions in P450BM-3 as compared with the microsomal 2B4 system. , 2000, Biochemistry.

[54]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[55]  G. Elizondo,et al.  CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity , 2000, Clinical pharmacology and therapeutics.

[56]  佐田 文宏.  CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12 : evidence for an allelic variant with altered catalytic activity , 2000 .

[57]  J. Peterson,et al.  How similar are P450s and what can their differences teach us? , 1999, Archives of biochemistry and biophysics.

[58]  A. Rettie,et al.  A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin , 1999, Epilepsy Research.

[59]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[60]  J. Peterson,et al.  Dynamics of protein-bound water in the heme domain of P450BM3 studied by high-pressure spectroscopy: comparison with P450cam and P450 2B4. , 1999, Biochemistry.

[61]  P. McDonagh,et al.  Crystal structure of the FMN‐binding domain of human cytochrome P450 reductase at 1.93 Å resolution , 1999, Protein science : a publication of the Protein Society.

[62]  I. Vakser,et al.  Identification of the Binding Site on Cytochrome P450 2B4 for Cytochrome b 5 and Cytochrome P450 Reductase* , 1998, The Journal of Biological Chemistry.

[63]  N. Bec,et al.  A central role for water in the control of the spin state of cytochrome P-450scc. , 1997, European Journal of Biochemistry.

[64]  A. P. Koley,et al.  Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.

[65]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[66]  A. P. Koley,et al.  Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. , 1996, Biochimie.

[67]  M. Alterman,et al.  Effect of different solubilizing agents on the aggregation state and catalytic activity of two purified rabbit cytochrome P450 isozymes, CYP1A2 (LM4) and CYP2B4 (LM2). , 1995, Biochemical and biophysical research communications.

[68]  C. Kasper,et al.  Role of Acidic Residues in the Interaction of NADPH-Cytochrome P450 Oxidoreductase with Cytochrome P450 and Cytochrome c(*) , 1995, The Journal of Biological Chemistry.

[69]  G. P. Kuznetsova,et al.  High-pressure-induced transitions in microsomal cytochrome P450 2B4 in solution: evidence for conformational inhomogeneity in the oligomers. , 1995, Archives of biochemistry and biophysics.

[70]  C. Di Primo,et al.  Antagonistic effects of hydrostatic pressure and osmotic pressure on cytochrome P-450cam spin transition. , 1995, Biophysical journal.

[71]  J Deisenhofer,et al.  Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.

[72]  V. Tsuprun,et al.  Cytochrome P‐450: hexameric structure of the purified LM4 form , 1993, FEBS letters.

[73]  G. H. Hoa,et al.  High pressure induced inactivation of ferrous cytochrome P-450 LM2 (IIB4) CO complex: evidence for the presence of two conformers in the oligomer. , 1992, Biochemical and Biophysical Research Communications - BBRC.

[74]  S. Sligar,et al.  Catalytic mechanism of cytochrome P-450: evidence for a distal charge relay , 1992 .

[75]  C. Di Primo,et al.  Heme-pocket-hydration change during the inactivation of cytochrome P-450camphor by hydrostatic pressure. , 1992, European journal of biochemistry.

[76]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[77]  S. Martinis,et al.  Crystal structure of the cytochrome P-450CAM active site mutant Thr252Ala. , 1991, Biochemistry.

[78]  P. Berndt,et al.  Immobilized cytochrome P‐450LM2 , 1990, FEBS letters.

[79]  C. Di Primo,et al.  Conformational changes of cytochromes P-450cam and P-450lin induced by high pressure. , 1989, Biochemistry.

[80]  R. Kraft,et al.  Electrostatic interactions between cytochrome P-450 LM2 and NADPH-cytochrome P-450 reductase. , 1988, Biomedica biochimica acta.

[81]  T. Poulos,et al.  High-resolution crystal structure of cytochrome P450cam. , 1987, Journal of molecular biology.

[82]  E. Orlova,et al.  Quaternary structure of the liver microsomal cytochrome P‐450 , 1986, FEBS letters.

[83]  B C Finzel,et al.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. , 1985, The Journal of biological chemistry.

[84]  S. Sligar,et al.  High-pressure investigations of cytochrome P-450 spin and substrate binding equilibria. , 1985, Archives of biochemistry and biophysics.

[85]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.